A total of 18,335, 11,286 and 13,115 dengue cases were recorded in Singapore in 2014, 2015 and 2016, respectively. (4) In 2017, however, we have seen a sustained reduction of approximately two-thirds of dengue cases in the months leading up to 22 September (cumulative total of 2,066 reported cases). (5) Project Wolbachia-Singapore is a new initiative that was started to combat dengue in the country. Male Aedes aegypti mosquitoes infected with Wolbachia (a naturally occurring bacteria) have been released in stages into the environment since October 2016. These male Wolbachia-carrying Aedes aegypti mosquitoes seek to mate with female Aedes aegypti, but the resulting eggs will not hatch (i.e. non-viable eggs) because the mating is biologically incompatible, thus leaving no offspring. (6) The subsequent reduction in dengue cases suggests that such new vector control measures have been successful. Although the number of dengue cases has been falling, countries in Southeast Asia (such as Thailand and Malaysia) and Latin America remain prime hotspots for the disease. With increasing air travel and greater mobility of both vector and human populations, the risk of imported dengue cases in Singapore is still high. (8) Locally, other mosquito-borne viruses, such as Chikungunya and Zika, also often present with similar clinical features. Some common overlapping symptoms include fever, myalgia, maculopapular exanthema, retro-orbital pain and lymphadenopathy. (9, 10) Prompt and accurate diagnosis continues to be important. The lower prevalence of dengue, however, mandates a change in our clinical approaches to febrile illnesses and a review of the use of dengue diagnostic tests. The wide spectrum of febrile illnesses and atypical dengue presentations poses a real challenge to clinicians. (11) Delayed diagnosis might lead to one or more of these unfortunate circumstances: (a) The patient will not be accorded the close vigilance required of dengue patients. (b) The patient will not be advised to monitor for danger signs. (c) The patient, who continues to be a reservoir of infection, will not be educated on vector bite prevention measures. (d) Potential dengue clusters may be missed due to a lack of epidemiological data. (e) Other unnecessary investigations, such as autoimmune markers or markers of myositis, may be ordered.
WHAT CAN I DO IN MY PRACTICE?
While dengue fever may be diagnosed clinically, laboratory tests can serve to confirm or secure a definitive diagnosis. Laboratory tests for dengue can be broadly categorised into definitive tests and nonspecific tests. Definitive tests include nonstructural protein 1 (NS1) antigen assay or dengue serology, while a complete blood count is an example of a nonspecific test. A 2011 study, which surveyed primary care physicians in Singapore,
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Definitive tests for dengue fever: when and which should I use? revealed that only about half of the physicians surveyed routinely ordered definitive tests for dengue; of these, three-quarters chose dengue serology testing. (12) 
Advantages of definitive tests
Definitive tests for dengue, including rapid point-of-care tests, allow for early identification and prompt notification. They are especially useful in managing the clinical uncertainties often encountered in primary care. Having a confirmed diagnosis would also be helpful for patient education and encouraging compliance to follow-up checks. A confirmed diagnosis also allows physicians to better provide patients with appropriate advice, including steps for vector-bite prevention, thereby limiting transmission of the illness.
When and which definitive test to use?
Dengue NS1 antigen test In general, direct virus detection methods are used to obtain an early, definitive and serotype-specific identification, if it has been less than five days from the time of fever onset. NS1 antigen testing can be conducted fairly rapidly, and at a lower cost, than other methods such as viral isolation or viral reverse transcriptase-polymerase chain reaction. Ordering a dengue NS1 antigen assay within the first week of symptom onset is one of the initial investigations recommended by the Ministry of Health, Singapore, for dengue infections.
(2) NS1 antigen is glycoprotein that is synthesised by all flaviviruses and secreted from infected mammalian cells during the acute phase of infection. (13) Most evaluations of the NS1 antigen assay mirror each other, indicating a moderately high sensitivity and very high specificity to dengue infection. (14, 15) There is also evidence that the sensitivity of NS1 antigen detection is higher in primary infection (> 90%) than in secondary infection (60%-80%). (16) High levels of NS1 antigen were also found to be correlated with higher levels of viraemia and, thus, could potentially be a predictor for severe illness. (16) (17) (18) (19) Dengue IgM/IgG serological test Immunoglobulin M (IgM) enzyme-linked immunosorbent assay (ELISA) and/or immunoglobulin G (IgG) ELISA are the tests of choice after the first five days of illness. In the later stages of illness, dengue serology is more useful, as NS1 antigen remains detectable for up to only nine days and the patient may thus test negative for dengue. (20) Dengue-specific IgM is usually expressed by Day 5 of illness onset and is present in higher levels than IgG in primary infection. (1, 21) Distinguishing between primary and secondary dengue is often not done in the primary care setting, as it may not be of practical relevance.
Available practical options
Physicians in both public and private practice can tap on laboratories in restructured hospitals or private laboratories for definitive dengue tests. While a patient's blood samples can be sent to the Environmental Health Institute laboratory at the National Environment Agency, the laboratory currently offers definitive testing only for the purpose of epidemiological surveillance. 
TAKE HOME MESSAGES
1. Dengue is a dynamic, systemic disease with a wide clinical spectrum that includes both severe and non-severe clinical manifestations.
Prompt diagnosis and notification are crucial for initiating
early vector control measures and early management, especially in atypical cases or when presented with a differential diagnosis. 3. In general, laboratory tests for dengue can be broadly categorised into nonspecific tests (e.g. complete blood count) and definitive tests (e.g. NS1 antigen test, dengue serology). 4. Definitive tests are useful for confirmation, as symptoms of early dengue overlap with those of many other febrile illnesses. 5. Dengue diagnostic results provide important epidemiological data and are crucial to initiate early vector control measures in the community. 6. Having a confirmed diagnosis allows the primary care physician to provide appropriate follow-up and patient education. 7. The NS1 antigen assay has a moderately high sensitivity and very high specificity to dengue infection. 8. NS1 antigen can be detected early in the course of illness, while positive serology is observed later on. 9. Primary care physicians have numerous laboratory options for definitive tests for dengue, including commercially available point-of-care test kits that incorporate both dengue NS1 antigen testing and serology. Visit the SMJ website: http://www.smj.org.sg/current-issue and select the appropriate quiz. You will be redirected to the SMA login page. For SMA member: (1) Log in with your username and password (if you do not know your password, please click on 'Forgot your password?'). (2) Select your answers for each quiz and click 'Submit'. For non-SMA member: (1) Create an SMJ CME account, or login with your SMJ CME username and password (for returning users). 
RESULTS:
(1) Answers will be published online in the SMJ January 2018 issue. (2) The MCR numbers of successful candidates will be posted online at the SMJ website by 3 January 2018.
Passing mark is 60%. No mark will be deducted for incorrect answers. (4) The SMJ editorial office will submit the list of successful candidates to the Singapore Medical Council.
(5) One CME point is awarded for successful candidates.
Deadline for submission: (November 2017 SMJ 3B CME programme): 12 noon, 27 December 2017.
